Regenerating the lost cardiomyocytes in Myocardial patients: Pitavastatin/Livalo, an inhibitor of HMG-CoA reductase and a blood cholesterol lowering drug, increases the expression of ERBB2 and promotes dedifferentiation of cardiomyocytes via down regulation of its target gene, 5/May/2014, 23.57

Small RNAs not only cure T2DM but also extend lifespan: MiRNA-146b increases UCP protein expression, energy expenditure, glucose tolerance, insulin sensitivity and extends lifespan via down regulation of its target gene, 5/May/2015, 23.45
May 5, 2015
Small molecule-based Lifespan extension therapy: Get1 inhibits senescence and extends life span by down regulating the expression of adenylate cyclase 5 (ADCY5), 6/May/2015, 11.19 am
May 6, 2015
Show all

A recent study from the Department of Biological Regulation, Weizmann Institute of Science, Rehovot 76100, Israel shows that “ERBB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation.” This study was published in the 6 April  2015 issue of the journal “Nature cell biology” (the number 1 journal in “Cell biology” research with an impact factor of 20.761) by Prof Tzahor ED’Uva G, and others.

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Regenerating the lost cardiomyocytes in Myocardial patients: Pitavastatin/Livalo, an inhibitor of HMG-CoA reductase and a blood cholesterol lowering drug, increases the expression of ERBB2 and promotes dedifferentiation  of cardiomyocytes via down regulation of its target gene

Significance: 

Given that: (1)  cardiovascular disease is the leading cause of death worldwide; (2) in India, in 2004, 14.6 lakhs deaths (14% of total deaths) were due to ischemic heart disease; and were expected to be doubled by 2015; and (3) the global economic cost spent in the treatment of cardiovascular disease in 2011 was little more than 10 billion US dollars, there is an urgent need to find a way to induce regeneration of cardiomyocytes that were lost in Myocardial patients.

This study suggests, for the first time, that Pitavastatin/Livalo, by decreasing the expression of its target gene, it may: (1) increase ERBB2 expression; and (2) induce cardiomycyte regeneration.  Thus, pharmacological formulations encompassing Pitavastatin/Livalo or its analogues may be used to promote cardiomyocyte regeneration following myocardial infarction

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Web: http://genomediscovery.org

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

To citeBoominathan, Regenerating the lost cardiomyocytes in Myocardial patients: Pitavastatin/Livalo, an inhibitor of HMG-CoA reductase and a blood cholesterol lowering drugincreases the expression of ERBB2 and promotes dedifferentiation  of cardiomyocytes via down regulation of its target gene, 5/May/2014, 23.57,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

* Research cooperation

Undisclosed information: How Pitavastatin/Livalo increases the expression of  ERBB2/Her2

Comments are closed.